Application Aside from their benefits for the treatment of type 2 diabetes and obesity, GLP-1 based drugs are beginning to be approved for the treatment of other conditions
Take-home messages A reduced barrier function with increased permeability or leaky gut has been associated with intestinal and extraintestinal diseases
doi: 10.3389/fonc.2024.1414946 Received 09 April 2024 Accepted 08 July 2024 Published 22 July 2024 Volume 14 - 2024 Edited by Gaetano Gallo, Sapienza University of Rome, Italy Reviewed by Sara Claudia Barone, Sapienza University of Rome, Italy Flaminia Genualdo, Sapienza University of Rome, Italy Updates Copyright 2024 Wei, Wang, Yu, Liu and Zong
Claims about medication efficacy are based on clinical studies and may not apply to all individuals
NR: n = 169), leptin ( x , R: n = 43
Das Ergebnis: Sie fhlen sich schneller und lnger satt, essen automatisch weniger und verlieren nachhaltig Gewicht ohne das typische Hungergefhl herkmmlicher Diten